Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04939246 · ClinicalTrials.gov registry record · NA
Stereotactic MRI-guided Adaptive Radiation Therapy (SMART) in One Fraction
A NA study of Metastatic Carcinoma, sponsored by Baptist Health South Florida.
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 2
- Study locations
NCT04939246 is a NA study of Metastatic Carcinoma that has completed, run by Baptist Health South Florida. The registered enrollment target is 30 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT04939246, a NA study of Metastatic Carcinoma, has completed, sponsored by Baptist Health South Florida.
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a multi-site single arm feasibility study of single-fraction Stereotactic MRI-guided Adaptive Radiation Therapy (SMART) for primary or metastatic carcinoma involving the lung, liver, adrenal gland, abdominal/pelvic lymph node, pancreas, and/or kidney. Stereotactic ablative body radiation therapy (SABR) is a highly-focused radiation treatment that gives an intense dose of radiation concentrated on a tumor, while limiting the dose to the surrounding organs.
Conditions Studied
Interventions
- RADIATION Stereotactic ablative body radiation therapy
Study Locations (2)
Florida
- Miami Cancer Institute at Baptist Health South Florida - Miami
Wisconsin
- University of Wisconsin Hospital and Clinics - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2021-06-18 |
| Est. Completion | 2024-07-17 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04939246
The ClinicalTrials.gov registry entry for NCT04939246 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baptist Health South Florida, which has 40 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Stereotactic ablative body radiation therapy is the first listed.
NCT04939246 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Florida, Wisconsin.
Frequently Asked Questions
What is clinical trial NCT04939246 about?
NCT04939246 is a clinical study titled "Stereotactic MRI-guided Adaptive Radiation Therapy (SMART) in One Fraction". This is a multi-site single arm feasibility study of single-fraction Stereotactic MRI-guided Adaptive Radiation Therapy (SMART) for primary or metastatic carcinoma involving the lung, liver, adrenal gland, abdominal/pelvic lymph node, pancreas, and/or kidney. Stereotactic ablative body radiation the...
What is the current status of trial NCT04939246?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2021-06-18. Estimated completion is 2024-07-17.
What conditions does trial NCT04939246 study?
This clinical trial studies the following conditions: Metastatic Carcinoma.
What interventions are being tested in trial NCT04939246?
The interventions under investigation include: Stereotactic ablative body radiation therapy (RADIATION).
Who is sponsoring clinical trial NCT04939246?
This trial is sponsored by Baptist Health South Florida, which has 40 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04939246 being conducted?
This trial has 2 study locations across Florida, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.